LT3371165T - Btk inhibitorius, naudojamas vėžiui gydyti - Google Patents
Btk inhibitorius, naudojamas vėžiui gydytiInfo
- Publication number
- LT3371165T LT3371165T LTEPPCT/US2016/060508T LT16060508T LT3371165T LT 3371165 T LT3371165 T LT 3371165T LT 16060508 T LT16060508 T LT 16060508T LT 3371165 T LT3371165 T LT 3371165T
- Authority
- LT
- Lithuania
- Prior art keywords
- treat cancer
- btk inhibitor
- inhibitor used
- btk
- cancer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562250575P | 2015-11-04 | 2015-11-04 | |
| US201662296143P | 2016-02-17 | 2016-02-17 | |
| US201662341189P | 2016-05-25 | 2016-05-25 | |
| PCT/US2016/060508 WO2017079542A1 (en) | 2015-11-04 | 2016-11-04 | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LT3371165T true LT3371165T (lt) | 2022-05-10 |
Family
ID=57442803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LTEPPCT/US2016/060508T LT3371165T (lt) | 2015-11-04 | 2016-11-04 | Btk inhibitorius, naudojamas vėžiui gydyti |
Country Status (23)
| Country | Link |
|---|---|
| US (4) | US20170119766A1 (lt) |
| EP (2) | EP4014977A1 (lt) |
| JP (4) | JP6913100B2 (lt) |
| KR (2) | KR102850604B1 (lt) |
| CN (2) | CN121622684A (lt) |
| AU (4) | AU2016349584B9 (lt) |
| BR (1) | BR112018007604B1 (lt) |
| CA (1) | CA3001735A1 (lt) |
| CY (1) | CY1125116T1 (lt) |
| DK (1) | DK3371165T3 (lt) |
| ES (1) | ES2912059T3 (lt) |
| HU (1) | HUE058323T2 (lt) |
| IL (2) | IL293093B2 (lt) |
| LT (1) | LT3371165T (lt) |
| MX (2) | MX388890B (lt) |
| NZ (1) | NZ741293A (lt) |
| PL (1) | PL3371165T3 (lt) |
| RS (1) | RS63146B1 (lt) |
| RU (1) | RU2765154C2 (lt) |
| SG (2) | SG10202005292UA (lt) |
| SI (1) | SI3371165T1 (lt) |
| TW (3) | TW202510883A (lt) |
| WO (1) | WO2017079542A1 (lt) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202510883A (zh) * | 2015-11-04 | 2025-03-16 | 德商默克專利有限公司 | 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法 |
| KR102780243B1 (ko) * | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
| US11186554B2 (en) * | 2017-05-03 | 2021-11-30 | Vivace Therapeutics, Inc. | Non-fused tricyclic compounds |
| EP3810590A1 (en) * | 2018-06-19 | 2021-04-28 | Merck Patent GmbH | Novel crystalline forms of 1-(4-{[6-amino-5-(4-phenoxy-phenyl)-pyrimidin-4-ylamino]-methyl}-4-fluoro-piperidin-1-yl)-propenone, salt forms thereof, and processes to obtain |
| US12168012B2 (en) | 2018-07-25 | 2024-12-17 | Novartis Ag | NLRP3 inflammasome inhibitors |
| AR119731A1 (es) | 2019-05-17 | 2022-01-05 | Novartis Ag | Inhibidores del inflamasoma nlrp3 |
| US12697333B2 (en) | 2020-01-08 | 2026-08-04 | Telios Pharma, Inc. | Methods of treating splenomegaly |
| UY39377A (es) | 2020-08-14 | 2022-03-31 | Novartis Ag | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos |
| CN112250666B (zh) * | 2020-10-09 | 2022-01-14 | 广东东阳光药业有限公司 | 取代的嘧啶类化合物及其用途 |
| JP2023551679A (ja) * | 2020-12-02 | 2023-12-12 | テリオス ファーマ， インコーポレイテッド | 眼科疾患を治療するための方法及び組成物 |
| TW202304889A (zh) * | 2021-04-03 | 2023-02-01 | 大陸商海南耀臻生物醫藥科技有限公司 | 作為fgfr抑制劑的雜環化合物及其應用 |
| US11866421B2 (en) | 2021-05-31 | 2024-01-09 | Epigen Biosciences, Inc. | Pyrimidine and pyridine amine compounds and usage thereof in disease treatment |
| US20250064805A1 (en) * | 2022-01-14 | 2025-02-27 | Telios Pharma Inc. | Methods of Treating Myeloproliferative Disorders Based on BTK Occupancy & Resynthesis Rate |
| US20260000669A1 (en) | 2022-06-24 | 2026-01-01 | Merck Patent Gmbh | Treatment regimen for autoimmune diseases and inflammatory diseases |
| UY40374A (es) | 2022-08-03 | 2024-02-15 | Novartis Ag | Inhibidores de inflamasoma nlrp3 |
| WO2026133229A1 (en) | 2024-12-20 | 2026-06-25 | Novartis Ag | Nlrp3 inflammasome inhibitors |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19649896A1 (de) * | 1996-12-02 | 1998-06-04 | Henkel Kgaa | Geformte Seifenprodukte |
| JP2002514195A (ja) * | 1996-12-05 | 2002-05-14 | アムジエン・インコーポレーテツド | 置換ピリミジン化合物およびそれの使用 |
| ES2364340T3 (es) * | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| JP2011500823A (ja) * | 2007-10-22 | 2011-01-06 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | Ｐｉ３キナーゼ阻害物質としてのピリドスルホンアミド誘導体 |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| US9073947B2 (en) * | 2011-06-10 | 2015-07-07 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with BTK inhibitory activity |
| UY34893A (es) * | 2012-07-10 | 2014-02-28 | Takeda Pharmaceutical | Derivados de azaindol |
| WO2014093230A2 (en) * | 2012-12-10 | 2014-06-19 | Merck Patent Gmbh | Compositions and methods for the production of pyrimidine and pyridine compounds with btk inhibitory activity |
| WO2014151620A1 (en) * | 2013-03-14 | 2014-09-25 | Boehringer Ingelheim International Gmbh | 5-thiazolecarboxamide dervatives and their use as btk inhibitors |
| KR20160060100A (ko) * | 2013-09-22 | 2016-05-27 | 칼리토르 사이언시즈, 엘엘씨 | 치환된 아미노피리미딘 화합물 및 이용 방법 |
| GB201404987D0 (en) * | 2014-03-20 | 2014-05-07 | Redx Pharma Ltd | Compounds |
| TW202510883A (zh) * | 2015-11-04 | 2025-03-16 | 德商默克專利有限公司 | 使用具有ｂｔｋ抑制活性之嘧啶及吡啶化合物治療癌症之方法 |
| KR102780243B1 (ko) * | 2015-11-17 | 2025-03-14 | 메르크 파텐트 게엠베하 | Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물을 사용하여 다발성 경화증을 치료하는 방법 |
-
2016
- 2016-11-04 TW TW113134429A patent/TW202510883A/zh unknown
- 2016-11-04 IL IL293093A patent/IL293093B2/en unknown
- 2016-11-04 SG SG10202005292UA patent/SG10202005292UA/en unknown
- 2016-11-04 RU RU2018120153A patent/RU2765154C2/ru active
- 2016-11-04 BR BR112018007604-0A patent/BR112018007604B1/pt active IP Right Grant
- 2016-11-04 WO PCT/US2016/060508 patent/WO2017079542A1/en not_active Ceased
- 2016-11-04 CA CA3001735A patent/CA3001735A1/en active Pending
- 2016-11-04 EP EP22152631.2A patent/EP4014977A1/en active Pending
- 2016-11-04 SG SG11201802927VA patent/SG11201802927VA/en unknown
- 2016-11-04 SI SI201631518T patent/SI3371165T1/sl unknown
- 2016-11-04 RS RS20220376A patent/RS63146B1/sr unknown
- 2016-11-04 MX MX2018005461A patent/MX388890B/es unknown
- 2016-11-04 NZ NZ741293A patent/NZ741293A/en unknown
- 2016-11-04 LT LTEPPCT/US2016/060508T patent/LT3371165T/lt unknown
- 2016-11-04 HU HUE16804956A patent/HUE058323T2/hu unknown
- 2016-11-04 KR KR1020187013350A patent/KR102850604B1/ko active Active
- 2016-11-04 DK DK16804956.7T patent/DK3371165T3/da active
- 2016-11-04 AU AU2016349584A patent/AU2016349584B9/en active Active
- 2016-11-04 TW TW105135943A patent/TWI783915B/zh active
- 2016-11-04 CN CN202511791621.0A patent/CN121622684A/zh active Pending
- 2016-11-04 TW TW111140026A patent/TWI858413B/zh active
- 2016-11-04 KR KR1020257027881A patent/KR20250133463A/ko active Pending
- 2016-11-04 US US15/343,570 patent/US20170119766A1/en not_active Abandoned
- 2016-11-04 CN CN201680077336.5A patent/CN108779095B/zh active Active
- 2016-11-04 JP JP2018543055A patent/JP6913100B2/ja active Active
- 2016-11-04 PL PL16804956T patent/PL3371165T3/pl unknown
- 2016-11-04 ES ES16804956T patent/ES2912059T3/es active Active
- 2016-11-04 EP EP16804956.7A patent/EP3371165B1/en active Active
-
2018
- 2018-04-26 IL IL258979A patent/IL258979B/en unknown
- 2018-04-30 MX MX2021015826A patent/MX2021015826A/es unknown
-
2020
- 2020-03-05 US US16/809,850 patent/US11491153B2/en active Active
-
2021
- 2021-04-16 US US17/232,383 patent/US20210244736A1/en not_active Abandoned
- 2021-07-09 JP JP2021113947A patent/JP7295169B2/ja active Active
- 2021-08-02 AU AU2021211982A patent/AU2021211982B2/en active Active
-
2022
- 2022-04-14 CY CY20221100282T patent/CY1125116T1/el unknown
-
2023
- 2023-05-30 AU AU2023203377A patent/AU2023203377A1/en not_active Abandoned
- 2023-06-08 JP JP2023094794A patent/JP2023105214A/ja active Pending
-
2024
- 2024-11-20 US US18/953,295 patent/US20250161304A1/en active Pending
- 2024-12-03 JP JP2024210583A patent/JP2025023232A/ja active Pending
-
2025
- 2025-06-10 AU AU2025204315A patent/AU2025204315A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL296080B1 (en) | Method for treating cancer | |
| IL255261A0 (en) | Methods for treating cancer | |
| LT3303334T (lt) | Tirozinkinazės inhibitoriai | |
| HUE049620T2 (hu) | Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal | |
| LT3137169T (lt) | Lizinui specifinės demetilazės-1 inhibitoriai | |
| HUE050564T2 (hu) | Lizinspecifikus demetiláz-1 inhibitorai | |
| IL258684A (en) | Combination therapy for treating malignancies | |
| PL3197456T3 (pl) | Leczenie nowotworów | |
| HUE058852T2 (hu) | Lizinspecifikus demetiláz-1 inhibitorai | |
| IL256206A (en) | Mct4 inhibitors for treating disease | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| DK3341479T3 (da) | LNA-G-Proces | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| EP3375108A4 (en) | SELECTIVE WIFI | |
| HUE057118T2 (hu) | Folyamat | |
| PT3134119T (pt) | Tratamento do cancro | |
| DK3197890T3 (da) | Disubstituerede diaryloxybenzoheterodiazolforbindelser | |
| EP3341117C0 (en) | Reactor | |
| EP3362091A4 (en) | COMBINATION THERAPY | |
| LT3534885T (lt) | Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui | |
| DK3256546T3 (da) | Depolymeriseringsfremgangsmåde | |
| DK3393478T3 (da) | Kombinationsterapi | |
| IL246558A0 (en) | Novel methods for treating cancer | |
| LT3383385T (lt) | Melflufeno dozavimo režimas vėžio atveju | |
| DK3374357T3 (da) | Disubstituerede diaryloxybenzoheterodiazol-forbindelser |